N-(4-Fluoro-2-methylbenzyl)-N-methylamine | 1249121-13-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-Fluoro-2-methylbenzyl)-N-methylamine
• 英文别名: 1-(4-fluoro-2-methylphenyl)-N-methylmethanamine
• CAS: 1249121-13-8
• 化学式: C₉H₁₂FN
• mdl: MFCD16622233
• 分子量: 153.2
• InChiKey: HSOBTJJNTLBNEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2020023355A1

  公开（公告）日：2020-01-30

  The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

  本发明提供了以下化合物（I）的公式：其中所有变量如本文所定义。这些化合物是色氨酸2,3-二氧化酶（IDO）的抑制剂，可用作治疗增殖性疾病，如癌症、病毒感染和/或自身免疫疾病的药物。
• Bicyclic pyrimidine derivatives
  申请人：Arai Hitoshi

  公开号：US20070037834A1

  公开（公告）日：2007-02-15

  [wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m+n is 4 or less; R 1 represents —NR 4 R 5 (wherein R 4 and R 5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R 2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, —C(═O)—, —SO 2 —, —OC(═O)— or the like; and R 3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like] Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related to T cells, such as an allergic disease, an autoimmune disease or transplant rejection.

  提供上述公式（I）所代表的双环嘧啶衍生物，其中m和n可以相同或不同，每个表示1至3的整数，其中m+n小于等于4；R1表示—NR4R5（其中R4和R5可以相同或不同，每个表示氢原子，取代或未取代的低碳基，取代或未取代的芳基烷基或类似物）；R2表示上述公式（II），公式（IV）或类似物；A表示单键，—C（═O）—，—SO2—，—OC（═O）—或类似物；R3表示取代或未取代的低碳基，取代或未取代的环烷基，取代或未取代的芳基烷基或类似物。还提供了上述公式（I）所代表的四元铵盐或药学上可接受的盐或类似物。这些化合物具有抗炎活性或对TARC和/或MDC功能的调节活性，并且用于治疗和/或预防与T细胞相关的疾病，例如过敏性疾病，自身免疫性疾病或移植排斥。
• [EN] NITROGEN CONTAINING 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS<br/>[FR] COMPOSÉS 2,3-DIHYDROQUINAZOLINE CONTENANT DE L'AZOTE SERVANT D'INHIBITEURS DE NAV1.8
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2022129281A1

  公开（公告）日：2022-06-23

  Compounds of formula (I) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (I), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions, such as atrial fibrillation.

  本文描述了公式(I)的化合物，其中每个变量组的定义如规范中所述。还描述了含有公式(I)化合物的制药组合物，以及使用这些化合物和制药组合物来抑制Nav1.8电压门控钠通道并治疗Nav1.8介导的疾病、障碍和病症，如疼痛和与疼痛相关的疾病、障碍和病症以及心血管疾病、障碍和病症，如心房颤动。
• [EN] TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS<br/>[FR] TRAITEMENT DU LUPUS, DE PATHOLOGIES FIBROGÈNES, ET DE MYOPATHIES INFLAMMATOIRES ET D'AUTRES TROUBLES EN UTILISANT DES INHIBITEURS DE LA KINASE PI3
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2014004470A1

  公开（公告）日：2014-01-03

  Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
• [EN] TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING P13 KINASE INHIBITORS<br/>[FR] TRAITEMENT DE LA POLYARTHRITE RHUMATOÏDE ET DE L'ASTHME À L'AIDE D'INHIBITEURS DE PI3 KINASE
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2014071105A1

  公开（公告）日：2014-05-08

  Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma.